Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Status:	Terminated
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	11/3/2018
Start Date:	July 13, 2015
End Date:	January 27, 2017

A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors

The purpose of this study is to determine whether the combination of Ulocuplumab and
Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung
cancer.

- Intervention model: Single group for Stage 1 DLT, then Parallel

- Data Monitoring Committee: No (Stage 1) Yes (Stage 2 Randomized Ph2)

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- SCLC or PAC that is advanced or has spread to other parts of the body

- Treated with at least one other chemotherapy that did not work or where cancer
relapsed

- Minimal limitations on activities of daily living as measured by Eastern Cooperative
Oncology Group (ECOG) score of 0-1

Exclusion Criteria:

- Patients with cancer that spread to the brain

- Active, known or suspected autoimmune disease

- Prior treatment with any drug that targets T cell co-stimulation pathways (such as
checkpoint inhibitors)

We found this trial at

sites

Local Institution

Helsinki, 00029

from

Helsinki,